Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines

Guy de Bruyn, Joyce Wang, Annie Purvis, Martin Sanchez Ruiz, Haritha Adhikarla, Saad Alvi, Matthew I Bonaparte, Daniel Brune, Agustin Bueso, Richard M Canter, Maria Angeles Ceregido, Sachin Deshmukh, David Diemert, Adam Finn, Remi Forrat, Bo Fu, Julie Gallais, Paul Griffin, Marie-Helene Grillet, Owen Haney, Jeffrey A Henderson, Marguerite Koutsoukos, Odile Launay, Federico Martinon Torres, Roger Masotti, Nelson L Michael, Juliana Park, Doris M Rivera M, Natalya Romanyak, Chris Rook, Lode Schuerman, Lawrence D Sher, Fernanda Tavares-Da-Silva, Ashley Whittington, Roman M Chicz, Sanjay Gurunathan, Stephen Savarino, Saranya Sridhar the VAT00002 booster cohorts study team
doi: https://doi.org/10.1101/2022.12.02.22282931

Article Information

doi 
https://doi.org/10.1101/2022.12.02.22282931
History 
  • December 3, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Guy de Bruyn, MD*,1,
  2. Joyce Wang, MS2,
  3. Annie Purvis, MSPH3,
  4. Martin Sanchez Ruiz, MD4,
  5. Haritha Adhikarla, PhD1,
  6. Saad Alvi, MD5,
  7. Matthew I Bonaparte, PhD1,
  8. Daniel Brune, MD6,
  9. Agustin Bueso, MD7,
  10. Richard M Canter, MS1,
  11. Maria Angeles Ceregido, PhD8,
  12. Sachin Deshmukh, MD9,
  13. David Diemert, MD10,
  14. Adam Finn, MD11,
  15. Remi Forrat, MD12,
  16. Bo Fu, PhD1,
  17. Julie Gallais, MS12,
  18. Paul Griffin, MBBS13,
  19. Marie-Helene Grillet, MD14,
  20. Owen Haney, PharmD1,
  21. Jeffrey A Henderson, MD15,
  22. Marguerite Koutsoukos, MS8,
  23. Odile Launay, MD16,
  24. Federico Martinon Torres, MD17,
  25. Roger Masotti, MS1,
  26. Nelson L Michael, MD18,
  27. Juliana Park, MD19,
  28. Doris M Rivera M, MD20,
  29. Natalya Romanyak, PharmD1,
  30. Chris Rook, MB21,
  31. Lode Schuerman, MD8,
  32. Lawrence D Sher, MD22,
  33. Fernanda Tavares-Da-Silva, MD8,†,
  34. Ashley Whittington, MD23,
  35. Roman M Chicz, PhD3,
  36. Sanjay Gurunathan, MD1,
  37. Stephen Savarino, MD1,†,
  38. Saranya Sridhar, DPhil24 and
  39. the VAT00002 booster cohorts study team‡
  1. 1Sanofi, Swiftwater, PA, USA
  2. 2Sanofi, Chengdu, China
  3. 3Sanofi, Cambridge, MA, USA
  4. 4Sanofi, Paris, France
  5. 5Chicago Clinical Research Institute, IL, USA
  6. 6Optimal Research, Peoria, IL, USA
  7. 7Demedica, San Pedro Sula, Honduras
  8. 8GSK, Wavre, Belgium
  9. 9Griffith University, Australia
  10. 10School of Medicine and Health Sciences, George Washington University, Washington, DC, USA
  11. 11Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
  12. 12Sanofi, Marcy l’Etoile, France
  13. 13Mater Health, Brisbane, Queensland, Australia. The University of Queensland, Brisbane, Queensland, Australia
  14. 14Sanofi, Lyon, France
  15. 15Black Hills Center for American Indian Health, SD, USA
  16. 16Université Paris Cité; Inserm, F-CRIN I REIVAC, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
  17. 17Pediatrics Department, Translational Pediatrics and Infectious Diseases Section, Santiago de Compostela, Spain; Genetics- Vaccines- Infectious Diseases and Pediatrics research group GENVIP, Instituto de Investigación Sanitaria de Santiago (IDIS), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
  18. 18Walter Reed Army Institute of Research, Silver Spring, MD, USA
  19. 19Sanofi, Sydney, Australia
  20. 20INVERIME S.A, Tegucigalpa, Honduras
  21. 21Cmax, Adelaide, Australia
  22. 22Peninsula Research Associates, Rolling Hills Estates, CA, USA
  23. 23London North West University Healthcare NHS Trust, London, UK
  24. 24Sanofi, Reading, UK
  1. ↵*Corresponding Author:
    Guy de Bruyn, Sanofi, Swiftwater, PA, USA, Guy.DeBruyn{at}sanofi.com; Tel: +15709725671
Back to top
Posted December 03, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines
Guy de Bruyn, Joyce Wang, Annie Purvis, Martin Sanchez Ruiz, Haritha Adhikarla, Saad Alvi, Matthew I Bonaparte, Daniel Brune, Agustin Bueso, Richard M Canter, Maria Angeles Ceregido, Sachin Deshmukh, David Diemert, Adam Finn, Remi Forrat, Bo Fu, Julie Gallais, Paul Griffin, Marie-Helene Grillet, Owen Haney, Jeffrey A Henderson, Marguerite Koutsoukos, Odile Launay, Federico Martinon Torres, Roger Masotti, Nelson L Michael, Juliana Park, Doris M Rivera M, Natalya Romanyak, Chris Rook, Lode Schuerman, Lawrence D Sher, Fernanda Tavares-Da-Silva, Ashley Whittington, Roman M Chicz, Sanjay Gurunathan, Stephen Savarino, Saranya Sridhar
medRxiv 2022.12.02.22282931; doi: https://doi.org/10.1101/2022.12.02.22282931
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area